LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | SB590885 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1242 | 5013 | 0.2479 | -0.0187 |
| MDA-MB-231 | PIK-93 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 2075 | 5013 | 0.4140 | 0.2064 |
| MDA-MB-231 | KIN001-043 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 2101 | 5013 | 0.4192 | 0.2134 |
| MDA-MB-231 | Alpelisib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 3498 | 5013 | 0.6978 | 0.5907 |
| MDA-MB-231 | Luminespib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 992 | 5013 | 0.1979 | -0.0864 |
| MDA-MB-231 | A443654 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 454 | 5013 | 0.0907 | -0.2315 |
| MDA-MB-231 | OSI-027 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 2254 | 5013 | 0.4497 | 0.2546 |
| MDA-MB-231 | XMD11-85h | 10.0 | uM | LJP6 | 72 | hr | 1311 | 2457 | 5013 | 0.4902 | 0.3096 |
| MDA-MB-231 | HG-6-64-01 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 824 | 5013 | 0.1644 | -0.1317 |
| MDA-MB-231 | WH-4-025 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1043 | 5013 | 0.2080 | -0.0726 |
| MDA-MB-231 | WZ-4-145 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 1546 | 5013 | 0.3084 | 0.0634 |
| MDA-MB-231 | XMD16-144 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 774 | 5013 | 0.1545 | -0.1452 |
| MDA-MB-231 | Brivanib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 4025 | 5013 | 0.8030 | 0.7331 |
| MDA-MB-231 | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 735 | 5013 | 0.1466 | -0.1558 |
| MDA-MB-231 | BX-912 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1207 | 5013 | 0.2408 | -0.0282 |
| MDA-MB-231 | Canertinib | 10.0 | uM | LJP6 | 72 | hr | 1311 | 699 | 5013 | 0.1396 | -0.1653 |
| MDA-MB-231 | Celastrol | 10.0 | uM | LJP6 | 72 | hr | 1311 | 815 | 5013 | 0.1627 | -0.1340 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 804 | 5013 | 0.1605 | -0.1370 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 625 | 5013 | 0.1247 | -0.1855 |
| MDA-MB-231 | CHIR-99021 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 3723 | 5013 | 0.7426 | 0.6514 |
| MDA-MB-231 | CP724714 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 4417 | 5013 | 0.8810 | 0.8389 |
| MDA-MB-231 | CP466722 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 4231 | 5013 | 0.8439 | 0.7886 |
| MDA-MB-231 | Crizotinib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1247 | 5013 | 0.2488 | -0.0174 |
| MDA-MB-231 | Momelotinib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1210 | 5013 | 0.2414 | -0.0274 |
| MDA-MB-231 | Dasatinib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1080 | 5013 | 0.2155 | -0.0625 |